araag2/HINT huggingface dataset:
Clinical trial NCT00701558 (phase 2, status: completed)
Conditions: non-small cell lung cancer metastatic
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib, gemcitabine
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  advanced and/or metastatic (stage IIIB/IV) unresectable non-small cell lung cancer;

          -  no previous systemic chemotherapy, radiation therapy or immunotherapy;

          -  Eastern Cooperative Oncology Group (ECOG) >=2.

        Exclusion Criteria:

          -  prior systemic anti-tumor therapy with human epidermal growth factor receptor 1
             (HER1/EGFR) inhibitors;

          -  active, non-controlled systemic disease;

          -  any other malignancies within 5 years (except for adequately treated cancer in situ of
             cervix, or basal or squamous cell skin cancer).
Clinical trial NCT01012037 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: linagliptin low dose, placebo, linagliptin medium dose
SMILES: CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1
Eligibility criteria:

        Inclusion criteria

          1. Diagnosis of type 2 diabetes mellitus.

          2. Current treatment with metformin alone (>/= 1500 mg or maximally tolerated dose) or
             metformin plus 1 other antidiabetic drug. Metformin must be administered in twice
             daily dosing regimen. Patients taking metformin three times daily can be included if
             posology is switched to twice daily and total daily dose is maintained.

          3. Glycosylated haemoglobin (HbA1c) is between 7.0% - 10.0%.

          4. Body Mass Index (BMI) </=45 kg/m2.

        Exclusion criteria

          1. Treatment with extended release metformin.

          2. Uncontrolled hyperglycaemia (fasting plasma glucose > 240 mg/dL or 13.3 mmol/L).

          3. Myocardial infarction (MI), stroke or transient ischaemic attack (TIA) within 6 months
             prior to informed consent.

          4. Impaired hepatic or renal function, or gastric bypass surgery.

          5. Treatment with glitazones, glucagon like peptide-1 (GLP-1) analogues/mimetics,
             antiobesity agents, or insulin within 3 months of informed consent.

          6. Current treatment with systemic steroids or change in dosage of thyroid hormones.

          7. Alcohol or drug abuse within 3 months of informed consent.

          8. Participation in another trial with investigational drug within 2 months prior to
             informed consent.

          9. Pre-menopausal women who are nursing, pregnant or not practicing an acceptable method
             of birth control.
Clinical trial NCT00954876 (phase 2, status: withdrawn)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine and cetuximab
SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
Reason stopped: 
    study has been terminated due to lack of accrual.
  
Eligibility criteria:

        Inclusion Criteria

          -  Metastatic colorectal cancer

          -  Tumor classified WT KRAS

          -  At least 18 yrs of age

          -  ECOG PS 0,1 or 2

          -  Evidence of adequate organ function

          -  Measurable disease per RECIST criteria

          -  Have at least two of the following criteria:

               -  Age > 65 years

               -  ECOG PS 1 or 2

               -  Serum Albumin < or equal to 3.5g/dL

               -  Prior RT to abdomen or pelvis

               -  Stopped first-line combination systemic chemotherapy < 6 weeks duration

        Exclusion Criteria

          -  Tumors classified as KRAS mutation

          -  Prior therapy with cetuximab, panitumumab or other agent that targets EGFR

          -  Prior exposure to any biologic

          -  Known sensitivity to cetuximab or 5-FU (or marked intolerance to 5-FU)

          -  Known DPD deficiency

          -  Uncontrolled angina or a myocardial infarction within the previous 12 months

          -  Concurrent severe uncontrolled medical illness

          -  Known uncontrolled CNS metastases

          -  Bowel disease associated with chronic diarrhea

          -  Major surgery within 28 days
Clinical trial NCT00429104 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: herceptin, gm-csf
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Histological confirmation of invasive carcinoma of the breast.

          2. HER-2/neu overexpression: 3+ by immunohistochemical staining or Fluorescence in situ
             hybridization (FISH) (+).

          3. Stage IV breast cancer with measurable disease.

          4. Patient receiving progressive disease after Herceptin plus chemotherapy or Herceptin
             alone. No more than two Herceptin containing regimens.

          5. Zubrod performance status 0 or 1.

          6. Adequate hematological parameters (White Blood cells-WBC > 3,000/mm3, platelet count >
             100,000/mm3), adequate renal function (serum creatinine < 2.0 mg/dl), adequate liver
             function (total bilirubin, aspartate aminotransferase (AST or SGOT) or alanine
             aminotransferase (ALT or SGPT) < 3 x normal).

        Exclusion Criteria:

          1. Active Brain metastasis.

          2. No measurable disease at the time of registration (e.g. bone only, leptomeningeal
             disease alone or pleural effusion alone).

          3. More than 2 Herceptin containing regimens in metastatic breast cancer.

          4. Known history of HIV positive.

          5. Chronic active hepatitis or cirrhosis.

          6. Symptomatic pulmonary disease.

          7. Use of steroid of non-steroidal anti-inflammatory analgesic or Cox-2 inhibitor 1 week
             prior to registration.
Clinical trial NCT00353301 (phase 2, status: completed)
Conditions: renal cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: erlotinib hydrochloride, sirolimus
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent to participate in this study.

          -  Histological diagnosis of renal cell carcinoma.

          -  Age greater or equal 18 years.

          -  Eastern Cooperative Oncology Group (ECOG) Performance status of 2 or better.

          -  Life expectancy of at least 3 months.

          -  Failure or intolerance to previous treatment with Sutent® and/or Nexavar®.

          -  Most recent systemic treatment at least 1 month from the beginning of treatment.

          -  Most recent local treatment (surgery or irradiation) > 2 weeks from the beginning of
             treatment.

          -  At least one site of measurable disease by CT scan or MRI (RECIST criteria).

          -  Baseline hemoglobin >9 g/dl, platelets > 100,000/mm3, absolute neutrophil count (ANC
             >1500/mm3.

        Exclusion Criteria:

          -  Previous treatment with Tarceva™, Iressa™, Rapamune™, temsirolimus or everolimus.

          -  Untreated metastasis to the central nervous system.

          -  Previous solid organ, bone marrow or stem-cell transplant.

          -  Known AIDS or HIV infection.

          -  Symptomatic or poorly controlled chronic heart failure.

          -  Chronic renal failure requiring dialysis on a regular basis.

          -  Chronic liver failure.

          -  Serum aspartate aminotransferase (AST), Alanine Aminotransferase (ALT), alkaline
             phosphatase or bilirubin >1.5 x the upper limit of normal for the local laboratory.

          -  Pregnant or breast-feeding women.

          -  Other invasive malignant diseases within 5 years (other than squamous or basal cell
             carcinoma of the skin).

          -  Inability to provide informed consent

          -  Any other serious and/or unstable medical, psychiatric, or other condition considered
             by the P.I. to preclude safe or reasonably compliant participation in the protocol.
Clinical trial NCT00182741 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: mitoxantrone hydrochloride, prednisone
SMILES: OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed prostate cancer

               -  Androgen-independent disease, defined as disease progression while on standard
                  hormonal management, including antiandrogen withdrawal

                    -  Patients must continue primary hormonal therapy during study treatment

               -  Regional or distant metastases

          -  Prostate-specific antigen > 5 ng/mL

          -  No brain metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 100

        Performance status

          -  ECOG 0-3

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Adequate hematologic function

        Hepatic

          -  Adequate hepatic function

        Renal

          -  Adequate renal function

          -  No calcium-salt kidney stones within the past 5 years

          -  No hypercalcemia

        Cardiovascular

          -  Adequate cardiac function

          -  No significant cardiac disease

          -  No atrial fibrillation

        Other

          -  Fertile patients must use effective barrier contraception during and for 2 months
             after completion of study treatment

          -  No other serious medical illness

          -  No other active malignancy except nonmelanoma skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 28 days since prior biologic therapy

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  See Disease Characteristics

        Radiotherapy

          -  No prior strontium chloride Sr 89

          -  More than 28 days since prior radiotherapy

          -  More than 56 days since prior samarium Sm 153 lexidronam pentasodium

        Surgery

          -  Prior prostatectomy and/or orchiectomy allowed

        Other

          -  More than 28 days since prior investigational therapy
Clinical trial NCT00636883 (phase 2, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    slow accrual rate
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patient's age between 18 and 75 years.

          2. Presence of microscopic diagnosis of pancreatic cancer.

          3. The disease is Locally advanced deemed by the surgeon to be unresectable, or
             metastatic disease.

          4. Karnofsky Performance status >50%.

          5. Prior radiotherapy for local diseases is allowed provided disease progression had been
             documented, and treatment completed at least 4 weeks before random assignment

          6. Prior chemotherapy is not permitted, except for fluorouracil given concurrently as a
             radiosensitizer.

          7. Patients must have normal organ function evidenced by

               -  Cr <1.5 ULN

               -  ANC >1000

               -  platelets> 100,000

               -  total bilirubin <1.5ULN.

          8. Pain should be controlled for at least two weeks without an increase in the narcotic
             consumption.

          9. Biliary obstruction should be controlled for at least two weeks evident by stable or
             improving liver function tests especially total bilirubin.

         10. Patient has signed a Patient Informed Consent Form.

         11. For all females of childbearing potential, a negative pregnancy test must be obtained
             within 72 hours before starting therapy.

        Exclusion Criteria:

          1. Contraindication to chemotherapy.

          2. Evidence of uncontrolled CNS disease (patients with controlled CNS disease for 4 weeks
             using the same imaging method and for whom are off steroid will be eligible)

          3. Uncontrolled Nausea and Vomiting

          4. Diagnosis of other malignancy in the last 5 years excluding non-melanoma skin cancer
             and in -situ cervical cancer.

          5. Subjects unlikely to comply with protocol, e.g. uncooperative attitude, inability to
             return for follow- up visits and unlikelihood of completing the study.

          6. Any known history of hypersensitivity to the study drugs.

          7. Pregnant or lactating women.

          8. Participation in a clinical trial with any investigational drug used with curative
             intent and within 30 days prior to study entry

          9. Peripheral sensitive neuropathy with functional impairment prior to study entry.
Clinical trial NCT01051414 (phase 2, status: completed)
Conditions: hepatitis c infection
ICD codes: B17.0
Drugs: bms-790052, bms-650032
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects chronically infected with HCV Genotype 1

          -  HCV RNA viral load of ≥ 10*5* IU/mL (100,000 IU/mL) at screening

        Exclusion Criteria:

          -  Subjects with evidence of liver cirrhosis

          -  Evidence of HCC

          -  Co-infection with hepatitis B virus, HIV
Clinical trial NCT00002684 (phase 2, status: completed)
Conditions: bladder cancer, urethral cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: cisplatin, ifosfamide, paclitaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically proven unresectable or metastatic urothelial cancer

               -  No transitional cell histologies

          -  Bidimensionally measurable disease

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Hematopoietic:

          -  WBC at least 3,500/mm^3

          -  Platelet count greater than 150,000/mm^3

        Hepatic:

          -  Bilirubin less than 2.0 mg/dL

        Renal:

          -  Creatinine less than 1.5 mg/dL OR

          -  Creatinine clearance greater than 55 mL/min

        Cardiovascular:

          -  No New York Heart Association class III or IV heart disease

        Other:

          -  No other concurrent malignancy except basal cell skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior systemic chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  At least 3 weeks since prior radiotherapy

        Surgery

          -  Not specified
Clinical trial NCT01311661 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: placebo twice daily, olodaterol low daily dose twice daily, olodaterol medium daily dose twice daily, placebo twice daily, olodaterol high daily dose once daily and placebo, olodaterol medium daily dose once daily and placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1
Eligibility criteria:

        Inclusion criteria:

          1. Patients of either sex.

          2. Aged 18 to 70 years.

          3. A current diagnosis and a documented minimum 3 month history of asthma Global
             Initiative for Asthma (GINA) treatment steps 3 and 4.

          4. Prebronchodilator Forced Expiratory Volume in one second (FEV1) >= 60% predicted and <
             90% predicted according to European Coal and Steel Community (ECSC).

          5. Increase in FEV1 >=12% and >=200 mL 15 min. after 400 µg salbutamol (albuterol);

          6. Stable on medium to high dose inhaled corticosteroids (ICS) or low to high dose ICS in
             combination with a long acting beta-adrenergics (LABA) for at least 6 weeks prior to
             screening. Stable on ICS mono component of the former fixed LABA/ICS treatment for at
             least 48 hours prior to Visit 1b.

        Exclusion criteria:

          1. Patients with a significant disease other than asthma.

          2. History of frequent seasonal exacerbations of asthma (defined as one or more seasonal
             exacerbations every year for the past three years).

          3. Upper respiratory tract infection in the past 3 weeks prior to screening visit 1b.

          4. Oral or other systemic corticosteroids in the past 6 weeks.

          5. Patients with allergen desensitization therapy if started within two years, if they
             are not on an established maintenance regimen characterized by dose adjustments but no
             further increase to the tolerable maximum in the same course of immunotherapy.
Clinical trial NCT00217282 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: oxaliplatin, gemcitabine, bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed non-small cell lung cancer, EXCEPT squamous cell cancer

          -  Stage IIIB or IV disease

          -  ECOG PS 0-1

          -  No prior treatment

          -  No brain metastases

          -  Must have measurable disease

        Exclusion Criteria:

          -  Deep vein thromboses or pulmonary embolus within 1 year

          -  History of gross hemoptysis
Clinical trial NCT00525161 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: sorafenib
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Reason stopped: 
    slow accrual and loss of funding
  
Eligibility criteria:

        Inclusion Criteria:

          -  All subjects must be female.

          -  Age ≥ 18 years old.

          -  Histologically proven carcinoma of the breast.

          -  Estrogen receptor and/or Progesterone positive disease.

          -  Metastatic or locally advanced disease.

          -  Patients on a preexisting endocrine agent for at least 3 months before enrollment.

          -  Have residual measurable disease after

               1. maximal response to endocrine therapy or

               2. no response to endocrine therapy or

               3. progressive non-visceral disease on endocrine therapy.

          -  Must be able to provide a tumor block from either the primary or metastatic site, if
             available.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.

          -  Adequate organ function.

        Exclusion Criteria:

          -  Patients with rapidly progressive disease on endocrine therapy who would otherwise be
             candidates for chemotherapy.

          -  Other coexisting malignancies, with the exception of basal cell carcinoma or cervical
             carcinoma in situ.

          -  Prior use of anti-angiogenic agents.

          -  As judged by the investigator, uncontrolled intercurrent illness.

          -  Known brain metastasis. Patients with neurological symptoms must undergo a CT scan/MRI
             of the brain to exclude brain metastasis.

          -  Treatment with a non-approved or investigational drug within 30 days before Day 1 of
             study treatment.

          -  Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's
             Wort.

          -  Known or suspected allergy to sorafenib or any agent given in the course of this
             trial.

          -  A serious non-healing wound or ulcer.

          -  Evidence or history of bleeding diathesis or coagulopathy.

          -  Major surgery, open biopsy or significant traumatic injury within the 4 weeks prior to
             the first dose of the study drug.

          -  Pulmonary hemorrhage/bleeding event ≥ Common Toxicity Criteria for Adverse Effects
             (CTCAE) Grade 2 within the 4 weeks prior to the first dose of study drug.

          -  Pregnancy

          -  Any condition that impairs patient's ability to swallow whole pills.

          -  Documented malabsorption problem.
Clinical trial NCT00107510 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: carboplatin, docetaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of breast cancer

               -  Clinical stage II or III disease (including T2-4, N0-3)

          -  No clinical or radiological evidence of distant metastases

               -  Isolated supraclavicular lymph node involvement allowed

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Sex

          -  Male or female

        Menopausal status

          -  Not specified

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  At least 3 months

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 10.0 g/dL

        Hepatic

          -  Bilirubin normal

          -  Meets 1 of the following criteria:

               -  AST or ALT ≤ 5 times upper limit of normal (ULN) AND alkaline phosphatase normal

               -  AST or ALT ≤ 1.5 times ULN AND alkaline phosphatase ≤ 2.5 times ULN

               -  AST or ALT normal AND alkaline phosphatase ≤ 5 times ULN

        Renal

          -  Creatinine clearance ≥ 30 mL/min

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 30 days after study
             treatment

          -  No active unresolved infection

          -  No history of severe hypersensitivity reaction to docetaxel, carboplatin, or any other
             drug formulated with polysorbate 80

          -  No known hypersensitivity to E. coli-derived proteins, filgrastim (G-CSF), or
             pegfilgrastim

          -  No peripheral neuropathy ≥ grade 2

          -  No other invasive malignancy within the past 5 years except curatively treated basal
             cell or squamous cell skin cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Surgery

          -  No prior surgical resection for invasive breast cancer

        Other

          -  No other prior therapy for invasive breast cancer